drugset

drugset / Trial / NCT04507126

A Pilot Study of the Effects of BCG Immunization on CSF and Blood-based Biomarkers in Older Adults.

NCT04507126 ↗

Phase 2 Completed 20 enrolled Massachusetts General Hospital

NaSingle-groupOpen-labelOther

Summary

A pilot study of the effects of Bacillus Calmette-Guérin (BCG) immunization on cerebrospinal fluid and blood-based biomarkers in older adults.

Timeline

Start: 2021-03-01
Primary completion: 2022-12-09
Completion: 2022-12-09

Publications

Weinberg MS, Kodali MC, Li Z, Galler JA, Tidball AR, Reynolds WC, Young C, Devitte-McKee K, Fatima HA, Kivisakk P, Chatterjee M, Kulkarni A, Billingsly JM, Bartlett AL, Sui SH, Kuhtreiber WM, Gerber J, McManus AJ, Tanzi RE, Das S, Faustman DL, Arnold SE. Bacillus Calmette-Guerin (BCG) immunotherapy reprograms CNS immunity and alters Alzheimer's biomarkers: results from two open-label clinical trials. Commun Med (Lond). 2026 Jul 2;6(1):358. doi: 10.1038/s43856-026-01691-7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bacillus Calmette-Guerin (BCG)	Vaccine	1.8e+06 unknown	Other
Subject	Bacillus Calmette-Guerin (BCG)	Vaccine	3.9e+06 unknown	Other

Indications

No indication recorded.